

ASX ANNOUNCEMENT

HAIR GROWTH PRODUCT SUPPLY AGREEMENT SIGNED WITH TAIWANESE MAYWUFA

- Cellmid signed an important agreement with Maywufa for the supply of its FGF5 inhibitor hair growth products
- Maywufa owns the largest pharmacy chain in Taiwan
- Planning expansion into China in 2016
- Global anti-aging hair care market is estimated at \$5billion

SYDNEY, Tuesday, 2 June 2015, Cellmid Limited (ASX: CDY) signed an important private label supply agreement with listed Taiwanese healthcare business, Maywufa Company Ltd (1731; Taiwan Stock Exchange). This is Cellmid's first private label entry into the estimated \$5 billion global hair growth and anti-aging hair care market.

According to the terms of the agreement Cellmid, through its wholly owned subsidiary Advangen Inc., will manufacture and sell to Maywufa FGF5 inhibitor hair growth products under their brand. Other terms of the agreement are not disclosed.

This is Cellmid's first private label contract combining the benefits of the established Taiwanese brand name, and Maywufa's extensive distribution channels, with Cellmid's cutting edge FGF5 inhibitor hair growth products.

Cellmid's FGF5 inhibitor hair growth products are scientifically and clinically validated to reduce hair loss and increase the number of growing hair follicles. They have been developed for moderate to medium level hair loss.

In a recent blinded, placebo controlled clinical study they showed a statistically significant 80.2% reduction in hair loss over 112 days (16 weeks) with twice daily use. Hair differentiation, or anagen/telogen ratio, improved with an increase of 44.2% in growing hair follicles during the same period as analysed by the Van Scott "hair pluck" method¹. Hair release and recovery was quantified by PhotoGrammetrix™ measurements and showed an improvement by a statistically significant 143.3%.

Selling the Company's FGF5 inhibitor products through private label supply agreements is a key expansion strategy for Cellmid. The Company is currently in negotiations with a number of international brand owners to grow this business further in the future. Utilising established brand names and distribution channels compliments Cellmid's drive to build its own évolis® brand.

Maywufa owns the largest pharmacy franchise in Taiwan with more than 200 stores. Its sales network covers over 5,000 drug stores, general practitioners and hospitals. In addition to its Pharmacy Franchise Maywufa has three other strategic businesses, including Haircare and Skincare, Medical Devices and Institutional Hospitals divisions.

Maywufa acts as exclusive distributor or agent to several large pharmaceutical and cosmetics companies representing major international brands as well as manufacturing

¹ Not less than 10 hair shafts were excised from the targeted region of the scalp and categorised as anagen or telogen. Ratios were calculated according to Van Scott.

and marketing products under its own Maywufa brand. Having won a number of industry awards for business excellence Maywufa is one of the leaders of Taiwan's booming healthcare sector. The company was founded in 1976 and is based in Taipei, Taiwan.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in oncology and nephropathy. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications and kidney diseases. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen Limited

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and products. Since then, Cellmid's FGF5 inhibitor assets have been consolidated in its wholly owned subsidiary, Advangen Limited. Cellmid, under Advangen Limited, has continued innovation and product development in addition to actively building distribution in Australia, China, Japan and other major markets. Since the acquisition of Advangen Inc., Advangen Limited filed a number of new patent applications covering several hair growth agents including midkine, pleiotrophin and a group of novel FGF5 inhibitors.

FGF5 inhibitor hair growth products

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 technologies and products. Since then, Cellmid's FGF5 inhibitor assets have been consolidated in its wholly owned subsidiary, Advangen Limited. Cellmid, under Advangen Limited, has continued innovation and product development in addition to actively building distribution in Australia, China, Japan and other major markets. Since the acquisition of Advangen Inc., Advangen Limited filed a number of new patent applications covering several hair growth agents including midkine, pleiotrophin and a group of novel FGF5 inhibitors

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.